Close Navigation
About Arix
Strategy
Overview
Investment Case
News
Results
Documents
Events
Calendar
Analysts
Stock info
Contact
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
12th June 2020
Useful Tools
Download, print or share this article
Print Article
Email Article
Save Article
Share Article
Twitter
LinkedIn
Facebook